TheStreet) -- Adam Feuerstein's take on the biotech week that was Nov. 19, 2010:
The week's best-performing stocks in the sector:
(APRI) (+29%) and
China Shenghuo Pharmaceutical Holdings
FDA advisory panel votes 13-2 to recommend the approval of
Human Genome Sciences'
(HGSI) lupus drug Benlysta. Read the
Human Genome FDA Panel Live Blog
Human Genome Hit by Benlysta Sales Worry
rumored to be eyeing a competing takeover offer for
says still on track to sign a major RNAi drug partnership before the end of the year.
> > Bull or Bear? Vote in Our Poll
said to be
shuttering health care hedge funds
in wake of insider -trading allegations. (via New York Times)
The week's worst-performing stocks:
Medicare panel endorses on-label use of
prostate cancer therapy Provenge.
rumored to be considering acquisition of Swiss biotech firm Actelion.
cuts 4,800 jobs in a corporate restructuring
axes the company's research efforts into RNAi drug
development. (via Pharmalot, In the Pipeline)
European regulators accept approval application for
lymphoma drug Pixuvri.
: Interim phase II ovarian and prostate cancer data for XL184.
FDA advisory panel votes 8-7 with one abstention to recommend approval of
MELAFind skin cancer detection device. Read the
MELA FDA Panel Live Blog
MELA Sciences Is Doomed
MELA Sciences: Not So Doomed
presents interim phase II data on limb ischemia drug.
presents phase II data on cholesterol drug.
Xgeva for prevention of bone fractures in cancer patients.
prices 8.8 million shares at $2.95 a share.
halt study of experimental blood thinner apixaban due to an increase in bleeding.
Results from late-stage study show
drug boosts good cholesterol levels and cuts bad cholesterol without safety risks
. (via Bloomberg)
Healthcare CEOs Make Big Dough
(via WSJ Health Blog)
Bayer Cuts Jobs
(via InVivo Blog)
sells 20 million shares at $4.40 a share.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to: